^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Basal Cell Carcinoma
    Drug:Erivedge (vismodegib) (Hedgehog cell-signalling pathway inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    07/31/2020
    Excerpt:
    ERIVEDGE (vismodegib) is a hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    11/14/2019
    Excerpt:
    Erivedge is indicated for the treatment of adult patients with...symptomatic metastatic basal cell carcinoma...locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    10/24/2019
    Excerpt:
    Basal cell skin cancer: Principle of systemic therapy…Systemic therapy options included: Hedgehogpathway inhibitors (ie, vismodegib, sonidegib).
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    JAMA Ophthalmol
    Title:

    Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial

    Excerpt:
    The median duration of exposure to vismodegib was 40.0 (IQR, 20.0-78.0) weeks, specifically 39.7 (IQR, 19.9-76.0) weeks for POLA-BCC and 92.4 (IQR, 53.2-163.0) weeks for metastatic BCC...70 (28.7%) achieved complete response, and 94 (38.5%) achieved partial response...Vismodegib was well tolerated by the study participants with POLA-BCC.
    DOI:
    10.1001/jamaophthalmol.2020.1539
    Trial ID:
    STEVIE